Table 3.
Diagnostic value of four anti–tumor‐associated antigen (TAA) autoantibodies in the validation cohort
| Anti‐TAA autoantibody | Positive (%) |
χ2 |
P | Sensitivity (%) | Specificity (%) | YI | Cutoff value | +LR | −LR | PPV (%) | NPV (%) | Accuracy (%) | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OC (n = 164) | NHS (n = 164) | ||||||||||||
| NPM1 | 27 (16.46) | 8 (4.88) | 11.55 | .001 | 16.46 | 95.12 | 0.1159 | 0.4685 | 3.38 | 0.88 | 77.14 | 53.24 | 55.79 |
| GNAS | 47 (28.66) | 8 (4.88) | 33.23 | <.001 | 28.66 | 95.12 | 0.2378 | 0.2248 | 5.88 | 0.75 | 85.45 | 57.14 | 61.89 |
| p53 | 57 (34.76) | 8 (4.88) | 46.07 | <.001 | 34.76 | 95.12 | 0.2988 | 0.3927 | 7.13 | 0.69 | 87.69 | 59.32 | 64.94 |
| KRAS | 8 (4.88) | 8 (4.88) | <0.01 | 1.000 | 4.88 | 95.12 | 0.0000 | 0.5234 | 1.00 | 1.00 | 50.00 | 50.00 | 50.00 |
Cutoff value: the 95th percentile of NHS was set up as the cutoff value.
Abbreviations: +LR, positive likelihood ratio; −LR, negative likelihood ratio; NHS, normal health sera; NPV, negative predictive value; OC, ovarian cancer; PPV, positive predictive value; YI, Youden’s index.